What It Is
ER-100 is an investigational gene therapy using a dual AAV2 vector system:
- Vector 1: AAV2 encoding tTA (tetracycline transactivator)
- Vector 2: AAV2 encoding polycistronic OSK (Oct4-P2A-Sox2-T2A-Klf4) under TRE promoter
Activation: OSK is expressed in the absence of doxycycline. Patients receive 8 weeks of systemic doxycycline to suppress OSK during initial expression, then withdraw doxycycline to activate OSK for ~8 weeks.
Key safety design choices:
- c-Myc deliberately excluded (primary oncogenic driver in full OSKM reprogramming)
- Post-mitotic RGCs cannot re-enter the cell cycle — intrinsic tumor-protection layer
- Tet-Off inducible system provides transcriptional shut-off switch
- Tissue-targeted (eye), not systemic
Identifiers: NCT07290244 · IND 138366 · FDA IND cleared January 15, 2026
Funding: Series D 240M; runway to H2 2027
Mechanism Summary
OSK partial reprogramming applies the three Yamanaka factors (without c-Myc) transiently and incompletely — far enough to reverse epigenetic age markers at CpG sites, but not far enough to induce pluripotency.
The foundational evidence (Lu et al. 2020, Nature, PMID 33268865):
- AAV2-delivered OSK intravitreal injection restored visual function and enabled axon regeneration after optic nerve crush in mice, including aged animals
- Zero tumor incidence after 10–18 months of continuous retinal OSK expression
- DNA methylation age reversal measured by Horvath pan-tissue and Skin&Blood clocks
What OSK does NOT do:
- Telomeres are NOT restored (no telomerase reactivation)
- Cellular identity is largely preserved, but the boundary between safe rejuvenation and dangerous dedifferentiation is not fully characterized
- The 63% seroprevalence of pre-existing AAV2 neutralizing antibodies (NAbs) in adults may reduce transduction efficiency
Mechanistic risk tensions:
- Jeanne Loring (Scripps Research) has publicly raised concern that doxycycline-inducible systems are inherently “leaky” — full silencing is not achieved in practice, raising tumor risk even with OSK-only partial reprogramming (ipscell.com, February 2026)
- Life Biosciences and FDA reviewers concluded the system is sufficiently controlled for Phase 1 to proceed — this is unresolved expert disagreement; human data will adjudicate
- Outcomes in the literature depend on promoter strength, delivery method, expression level, and duration — the ER-100 design represents one specific configuration
Evidence Summary
| Claim | Grade | Source |
|---|---|---|
| FDA IND cleared January 2026; first partial reprogramming human trial | Confirmed | NCT07290244, IND 138366 |
| Phase 1 initiated January 2026; actively enrolling | Confirmed | ClinicalTrials.gov |
| OSK (no c-Myc) reverses epigenetic age in mouse RGCs | Confirmed | Lu et al. 2020, Nature |
| NHP study: ER-100 safety + visual function improvement | Supported | Ksander et al., IOVS 2023 (abstract only; not peer-reviewed) |
| No teratomas in mice with OSK-only after 10–18 months | Confirmed | Lu et al. 2020 |
| Human efficacy: ER-100 reverses aging or improves vision | Gap | No human data exist |
| Human safety: ER-100 is safe | Gap | Phase 1 just started |
| Leaky Tet-On system poses teratoma risk | Contested | Expert disagreement; unresolved |
| Altos Labs registered Phase 1 OSK trial for AMD | Reported (unverified) | No NCT confirmed |
Why It Matters for Vitals
ER-100 is the highest-plausibility intervention for addressing epigenetic information loss as a root cause of aging — but also the lowest readiness. The gap between “safe in Phase 1” and “proven to extend human healthspan or lifespan” is enormous.
Vitals relevance is currently speculative. No consumer or medical wearable measures DNA methylation, gene expression, senescence markers, or retinal ganglion cell function. The most plausible monitoring framework would be periodic blood-based epigenetic clock measurement (Horvath/GrimAge via CLIA lab) — not wearables.
Competitive context: Altos Labs ($3B+ Bezos-backed) is the best-capitalized competitor in partial reprogramming. Its claimed April 2026 Phase 1 AMD trial has no confirmed NCT number and should be treated as unverified.
Regulatory reality: The FDA does not recognize aging as a disease. All trials require named disease indications. A dedicated aging indication would require a separate regulatory strategy.
Risks and Uncertainty
- No human data: Phase 1 initiated January 2026; no SAEs, AEs, or interim analyses publicly available
- NHP data not peer-reviewed: primate efficacy presented only as conference abstract (ARVO 2023, AAO 2024)
- Optic nerve injury models ≠ natural aging: primary preclinical data are crush injury models in young adult mice — significant category error if extrapolated to systemic aging reversal
- Dose not publicly confirmed: company has not issued official dose statement; patent-derived estimates are informative but not confirmed
- Doxycycline regimen specifics unclear: precise dosing, vitreous PK, and minimum suppression concentration unestablished
- Systemic extrapolation unjustified: eye is immune-privileged; systemic OSK delivery faces entirely different tissue-specificity and safety challenges
- AAV2 NAb seroprevalence ~63% globally: may reduce transduction efficiency and affect trial eligibility
- AAV gene therapy manufacturing complexity: dual-vector system doubles batch requirements, cold chain burden, and regulatory comparability burden
Best Stack Context
Not applicable — ER-100 is not in any clinical or experimental stack context for Vitals users. It is years from any guideline or coaching use.
What Stays Inside This Hub
The following are kept inline and not split into separate notes:
- Formulation and dual-vector design details
- Manufacturing complexity and cold chain logistics
- Regulatory pathway analysis (beyond the IND/Phase 1 facts)
- Competitive landscape (Altos Labs, Turn Bio, Rejuvenate Bio, BioViva)
- Cost estimates (Luxturna precedent: $425,000/eye)
- The eye as proof-of-concept rationale
- Disease context (OAG and NAION unmet need)
These are compound-specific details with no current Vitals coaching relevance.
Related Notes
- Epigenetic Reprogramming (aspirational — mechanism note not yet created)
- NAION (if/when optic neuropathy MOC exists)
- GLP-1 RA NAION Safety Signal (related safety context for optic nerve)
- Biological Age (epigenetic clock context — Horvath/GrimAge)
- Vitals Knowledge Map (entry point)
Source: Canonical monograph — skills/knowledge-base/er-100-life-biosciences-partial-epigenetic-reprogramming-human-trial/er-100-life-biosciences-partial-epigenetic-reprogramming-human-trial.md
DO_NOT_OPERATIONALIZE_YET: true — HUMAN_SIGN_OFF_REQUIRED: true